NCT02990221View on ClinicalTrials.gov

Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 12, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

July 30, 2018

Conditions
Actinic Keratosis
Interventions
DRUG

Ingenol mebutate

150 mcg / g per day, to be applied on a predetermined area of 25 cm2 of skin of the face or scalp, for 3 days consecutive

PROCEDURE

cryotherapy

application with 5 seconds of freezing time of each lesion located in a predetermined skin area of 25 cm2 of the face or scalp

Trial Locations (1)

80131

Second University of Naples, Naples

All Listed Sponsors
lead

University of Campania Luigi Vanvitelli

OTHER

NCT02990221 - Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy | Biotech Hunter | Biotech Hunter